Intraperitoneal PD-1 monoclonal antibody for the treatment of advanced primary liver cancer with malignant ascites: a single-arm, single-center, phase Ib trial
-
Published:2024-01
Issue:1
Volume:9
Page:102206
-
ISSN:2059-7029
-
Container-title:ESMO Open
-
language:en
-
Short-container-title:ESMO Open
Author:
Chen C.,
Li Z.,
Xiong X.,
Yao A.,
Wang S.,
Liu X.,
Liu X.,
Wang J.ORCID
Subject
Cancer Research,Oncology
Reference25 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021
2. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008
3. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial;Cheng;Lancet Oncol,2009
4. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study;Rimassa;Lancet Oncol,2018
5. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study;Llovet;J Clin Oncol,2013